Huub J van Eyk1, Elisabeth H M Paiman2, Maurice B Bizino3, Suzanne L IJzermans4, Fleur Kleiburg4, Tim G W Boers2, Eline J Rappel2, Jedrzej Burakiewicz2, Hermien E Kan2, Johannes W A Smit5, Hildo J Lamb2, Ingrid M Jazet4, Patrick C N Rensen4. 1. Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands. Electronic address: H.J.van_Eyk@lumc.nl. 2. Dept. Radiology, LUMC, Leiden, the Netherlands. 3. Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Dept. Radiology, LUMC, Leiden, the Netherlands. 4. Dept. Medicine, Div. Endocrinology, Leiden University Medical Center (LUMC), Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands. 5. Dept. Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Abstract
BACKGROUND AND AIMS: Several studies have shown that glucagon-like peptide-1 (GLP-1) analogues can affect resting energy expenditure, and preclinical studies suggest that they may activate brown adipose tissue (BAT). The aim of the present study was to investigate the effect of treatment with liraglutide on energy metabolism and BAT fat fraction in patients with type 2 diabetes. METHODS AND RESULTS: In a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after treatment for 4, 12 and 26 weeks, we assessed resting energy expenditure (REE) by indirect calorimetry. Furthermore, at baseline and after 26 weeks, we determined the fat fraction in the supraclavicular BAT depot using chemical-shift water-fat MRI at 3T. Liraglutide reduced REE after 4 weeks, which persisted after 12 weeks and tended to be present after 26 weeks (week 26 vs baseline: liraglutide -52 ± 128 kcal/day; P = 0.071, placebo +44 ± 144 kcal/day; P = 0.153, between group P = 0.057). Treatment with liraglutide for 26 weeks did not decrease the fat fraction in supraclavicular BAT (-0.4 ± 1.7%; P = 0.447) compared to placebo (-0.4 ± 1.4%; P = 0.420; between group P = 0.911). CONCLUSION: Treatment with liraglutide decreases REE in the first 12 weeks and tends to decrease this after 26 weeks without affecting the fat fraction in the supraclavicular BAT depot. These findings suggest reduction in energy intake rather than an increase in REE to contribute to the liraglutide-induced weight loss. TRIAL REGISTRY NUMBER: NCT01761318.
RCT Entities:
BACKGROUND AND AIMS: Several studies have shown that glucagon-like peptide-1 (GLP-1) analogues can affect resting energy expenditure, and preclinical studies suggest that they may activate brown adipose tissue (BAT). The aim of the present study was to investigate the effect of treatment with liraglutide on energy metabolism and BAT fat fraction in patients with type 2 diabetes. METHODS AND RESULTS: In a 26-week double-blind, placebo-controlled trial, 50 patients with type 2 diabetes were randomized to treatment with liraglutide (1.8 mg/day) or placebo added to standard care. At baseline and after treatment for 4, 12 and 26 weeks, we assessed resting energy expenditure (REE) by indirect calorimetry. Furthermore, at baseline and after 26 weeks, we determined the fat fraction in the supraclavicular BAT depot using chemical-shift water-fat MRI at 3T. Liraglutide reduced REE after 4 weeks, which persisted after 12 weeks and tended to be present after 26 weeks (week 26 vs baseline: liraglutide -52 ± 128 kcal/day; P = 0.071, placebo +44 ± 144 kcal/day; P = 0.153, between group P = 0.057). Treatment with liraglutide for 26 weeks did not decrease the fat fraction in supraclavicular BAT (-0.4 ± 1.7%; P = 0.447) compared to placebo (-0.4 ± 1.4%; P = 0.420; between group P = 0.911). CONCLUSION: Treatment with liraglutide decreases REE in the first 12 weeks and tends to decrease this after 26 weeks without affecting the fat fraction in the supraclavicular BAT depot. These findings suggest reduction in energy intake rather than an increase in REE to contribute to the liraglutide-induced weight loss. TRIAL REGISTRY NUMBER: NCT01761318.
Authors: Mila S Welling; Cornelis J de Groot; Lotte Kleinendorst; Bibian van der Voorn; Jan Steven Burgerhart; Eline S van der Valk; Mieke M van Haelst; Erica L T van den Akker; Elisabeth F C van Rossum Journal: Clin Obes Date: 2021-07-21